UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000023162
Receipt number R000026361
Scientific Title A multicenter randomized phase II clinical trial with neo -adjuvant chemotherapy containing eribulin mesylate for triple negative primary breast cancer patients (Neo-Entrance study)
Date of disclosure of the study information 2016/09/15
Last modified on 2022/01/20 10:47:53

No. Disposal Last modified on Item of update
1 Insert 2016/07/14 11:15:26
2 Update 2016/09/14 10:22:05 Anticipated trial start date
3 Update 2016/10/12 10:15:42 UMIN ID1
4 Update 2017/02/16 10:27:51 Public title
Acronym
5 Update 2017/02/16 10:35:07 Recruitment status
6 Update 2017/07/24 09:49:36 Anticipated trial start date
7 Update 2018/01/15 15:10:09 Institutions
8 Update 2018/08/23 17:47:05 Acronym
9 Update 2019/07/18 20:13:07 Recruitment status
Date of IRB
Last follow-up date
10 Update 2019/09/05 16:14:42 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
11 Update 2019/09/05 16:15:07 Number of participants that the trial has enrolled
12 Update 2020/01/21 13:42:52 Division name
13 Update 2020/02/05 17:23:38 Anticipated trial start date
Last follow-up date
14 Update 2021/06/16 15:20:19
Last name of contact person

Last name of contact person
Organization
Homepage URL
Name of person sending information
Name of person sending information
Organization
Division name
Institute
15 Update 2022/01/20 10:47:53 Email
Email